167 related articles for article (PubMed ID: 22719951)
1. Attenuation of soft-tissue sarcomas resistance to the cytotoxic action of TNF-α by restoring p53 function.
Muret J; Hasmim M; Stasik I; Jalil A; Mallavialle A; Nanbakhsh A; Lacroix L; Billot K; Baud V; Thiery J; Vielh P; Terrier P; Wiels J; Vassilev L; Lecesne A; Bonvalot S; Chouaib S
PLoS One; 2012; 7(6):e38808. PubMed ID: 22719951
[TBL] [Abstract][Full Text] [Related]
2. Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling.
Pishas KI; Neuhaus SJ; Clayer MT; Schreiber AW; Lawrence DM; Perugini M; Whitfield RJ; Farshid G; Manavis J; Chryssidis S; Mayo BJ; Haycox RC; Ho K; Brown MP; D'Andrea RJ; Evdokiou A; Thomas DM; Desai J; Callen DF; Neilsen PM
Cancer Res; 2014 Feb; 74(3):921-31. PubMed ID: 24336067
[TBL] [Abstract][Full Text] [Related]
3. Nutlin-3a is a potential therapeutic for ewing sarcoma.
Pishas KI; Al-Ejeh F; Zinonos I; Kumar R; Evdokiou A; Brown MP; Callen DF; Neilsen PM
Clin Cancer Res; 2011 Feb; 17(3):494-504. PubMed ID: 21098696
[TBL] [Abstract][Full Text] [Related]
4. Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma.
Ohnstad HO; Castro R; Sun J; Heintz KM; Vassilev LT; Bjerkehagen B; Kresse SH; Meza-Zepeda LA; Myklebost O
Cancer; 2013 Mar; 119(5):1013-22. PubMed ID: 23165797
[TBL] [Abstract][Full Text] [Related]
5. p53 status correlates with histopathological response in patients with soft tissue sarcomas treated using isolated limb perfusion with TNF-alpha and melphalan.
Muret J; Yacoub M; Terrier P; Drusch F; Laplanche A; Gaudin C; Richon C; Le Péchoux C; Le Cesne A; Lejeune FJ; Tursz T; Fouret P; Bonvalot S; Chouaib S
Ann Oncol; 2008 Apr; 19(4):793-800. PubMed ID: 18065405
[TBL] [Abstract][Full Text] [Related]
6. MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines.
Ohnstad HO; Paulsen EB; Noordhuis P; Berg M; Lothe RA; Vassilev LT; Myklebost O
BMC Cancer; 2011 May; 11():211:1-11. PubMed ID: 21624110
[TBL] [Abstract][Full Text] [Related]
7. MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status.
Flørenes VA; Maelandsmo GM; Forus A; Andreassen A; Myklebost O; Fodstad O
J Natl Cancer Inst; 1994 Sep; 86(17):1297-302. PubMed ID: 8064888
[TBL] [Abstract][Full Text] [Related]
8. Adenovirus-mediated p53 gene therapy in pediatric soft-tissue sarcoma cell lines: sensitization to cisplatin and doxorubicin.
Ganjavi H; Gee M; Narendran A; Freedman MH; Malkin D
Cancer Gene Ther; 2005 Apr; 12(4):397-406. PubMed ID: 15618970
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma.
Drakos E; Thomaides A; Medeiros LJ; Li J; Leventaki V; Konopleva M; Andreeff M; Rassidakis GZ
Clin Cancer Res; 2007 Jun; 13(11):3380-7. PubMed ID: 17545546
[TBL] [Abstract][Full Text] [Related]
10. Suppression of MMP-2 attenuates TNF-α induced NF-κB activation and leads to JNK mediated cell death in glioma.
Kesanakurti D; Chetty C; Bhoopathi P; Lakka SS; Gorantla B; Tsung AJ; Rao JS
PLoS One; 2011 May; 6(5):e19341. PubMed ID: 21573233
[TBL] [Abstract][Full Text] [Related]
11. MDM2 Inhibition in a Subset of Sarcoma Cell Lines Increases Susceptibility to Radiation Therapy by Inducing Senescence in the Polyploid Cells.
Das S
Adv Radiat Oncol; 2020; 5(2):250-259. PubMed ID: 32280825
[TBL] [Abstract][Full Text] [Related]
12. Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A.
Müller CR; Paulsen EB; Noordhuis P; Pedeutour F; Saeter G; Myklebost O
Int J Cancer; 2007 Jul; 121(1):199-205. PubMed ID: 17354236
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a.
Fontana MC; Nanni J; Ghelli Luserna di Rorà A; Petracci E; Padella A; Ghetti M; Ferrari A; Marconi G; Soverini S; Iacobucci I; Papayannidis C; Curti A; Audisio E; Giannini MB; Rondoni M; Lanza F; Cavo M; Martinelli G; Simonetti G
Biomedicines; 2021 Apr; 9(4):. PubMed ID: 33917342
[TBL] [Abstract][Full Text] [Related]
14. Activation of p53 by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells.
Hasegawa H; Yamada Y; Iha H; Tsukasaki K; Nagai K; Atogami S; Sugahara K; Tsuruda K; Ishizaki A; Kamihira S
Leukemia; 2009 Nov; 23(11):2090-101. PubMed ID: 19710698
[TBL] [Abstract][Full Text] [Related]
15. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.
Kojima K; Konopleva M; McQueen T; O'Brien S; Plunkett W; Andreeff M
Blood; 2006 Aug; 108(3):993-1000. PubMed ID: 16543464
[TBL] [Abstract][Full Text] [Related]
16. Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).
Drakos E; Singh RR; Rassidakis GZ; Schlette E; Li J; Claret FX; Ford RJ; Vega F; Medeiros LJ
Leukemia; 2011 May; 25(5):856-67. PubMed ID: 21394100
[TBL] [Abstract][Full Text] [Related]
17. Pre-activation of the p53 pathway through Nutlin-3a sensitises sarcomas to drozitumab therapy.
Pishas KI; Neuhaus SJ; Clayer MT; Adwal A; Brown MP; Evdokiou A; Callen DF; Neilsen PM
Oncol Rep; 2013 Jul; 30(1):471-7. PubMed ID: 23670273
[TBL] [Abstract][Full Text] [Related]
18. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells.
Mir R; Tortosa A; Martinez-Soler F; Vidal A; Condom E; Pérez-Perarnau A; Ruiz-Larroya T; Gil J; Giménez-Bonafé P
Int J Cancer; 2013 Apr; 132(7):1525-36. PubMed ID: 22961628
[TBL] [Abstract][Full Text] [Related]
19. Expression of apoptosis-related proteins, p53, and DNA fragmentation in sarcomas of the pulmonary artery.
Gaumann A; Tews DS; Mayer E; Dahm M; Petrow PK; Otto M; Kirkpatrick CJ; Kriegsmann J
Cancer; 2001 Sep; 92(5):1237-44. PubMed ID: 11571738
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression.
Palani CD; Beck JF; Sonnemann J
Invest New Drugs; 2012 Feb; 30(1):25-36. PubMed ID: 20680659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
